EPO and hydrops fetalis: These agents, which favorably affect prognosis both in CKD and HF, increase hemoglobin by approximately 0.6–0.7 g/dL, an effect that has been linked to a rise in EPO and an expansion in red blood cell mass that alleviate anemia [125].